# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K080069   
B. Purpose for Submission: Transfer of ownership of 510(k) C. Measurand: D-Dimer   
D. Type of Test: Latex Immuno Assay   
E. Applicant: American Diagnostica Inc.   
F. Proprietary and Established Names: DIMERTEST® G. Regulatory Information:

1. Regulation section: 864.7320

2. Classification: II

3. Product code: DAP

4. Panel: Hematology

# H. Intended Use:

1. Intended use(s): The DIMERTEST® latex kit is intended for the rapid qualitative or semi-quantitative evaluation of circulating derivatives of cross-linked fibrin degradation products (D-dimer) in human plasma.

2. Indication(s) for use: same as Intended Use.

3. Special conditions for use statement(s): N/A

4. Special instrument requirements: N/A

# I. Device Description:

The kit is comprised of: latex reagent (latex beads coupled with murine anti-D-Dimer monoclonal antibody), positive control, negative control, buffer, test cards, and stirrers.

# J. Substantial Equivalence Information:

1. Predicate device name(s): DIMERTEST®

2. Predicate K number(s): K974596

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>510(k)</td><td rowspan=1 colspan=1>Same as predicate</td><td rowspan=1 colspan=1>K974596</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>510(k)</td><td rowspan=1 colspan=1>No differences</td><td rowspan=1 colspan=1>K974596</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable): N/A

L. Test Principle: see K974596

M. Performance Characteristics (if/when applicable):

1. Analytical performance: see K974596 a. Precision/Reproducibility: b. Linearity/assay reportable range: c. Traceability, Stability, Expected values (controls, calibrators, or methods): d. Detection limit: e. Analytical specificity: f. Assay cut-off:

2. Comparison studies: see K974596 a. Method comparison with predicate device:

b. Matrix comparison:

3. Clinical studies: N/A a. Clinical Sensitivity:

b. Clinical specificity: c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off: see K974596

5. Expected values/Reference range: see K974596

N. Proposed Labeling: see K974596

# O. Conclusion:

1. The submitted information in this premarket notification is complete and supports a substantial equivalence decision.